Home › Compare › EQRXW vs NOBL

EQRXW vs NOBL: Dividend Comparison 2026

EQRXW yields 4395.60% · NOBL yields 4.00%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EQRXW wins by $17844003331690.01M in total portfolio value
10 years
EQRXW
EQRXW
● Live price
4395.60%
Share price
$0.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$17844003331690.04M
Annual income
$17,079,643,292,413,290,000.00
Full EQRXW calculator →
NOBL
NOBL
● Live price
4.00%
Share price
$50.00
Annual div
$2.00
5Y div CAGR
5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$28.0K
Annual income
$899.19
Full NOBL calculator →

Portfolio growth — EQRXW vs NOBL

📍 EQRXW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEQRXWNOBL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EQRXW + NOBL cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
EQRXW pays
NOBL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EQRXW
Annual income on $10K today (after 15% tax)
$373,626.37/yr
After 10yr DRIP, annual income (after tax)
$14,517,696,798,551,296,000.00/yr
NOBL
Annual income on $10K today (after 15% tax)
$340.00/yr
After 10yr DRIP, annual income (after tax)
$764.31/yr
At 15% tax rate, EQRXW beats the other by $14,517,696,798,551,296,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EQRXW + NOBL for your $10,000?

EQRXW: 50%NOBL: 50%
100% NOBL50/50100% EQRXW
Portfolio after 10yr
$8922001665845.04M
Annual income
$8,539,821,646,206,645,000.00/yr
Blended yield
95.72%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EQRXW buys
0
NOBL buys
0
No recent congressional trades found for EQRXW or NOBL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEQRXWNOBL
Forward yield4395.60% ✓4.00%
Annual dividend / share$2.00$2.00
Payout ratio50%50%
1-year div growth0%5% ✓
5-year div CAGR0%5% ✓
Portfolio after 10y$17844003331690.04M ✓$28.0K
Annual income after 10y$17,079,643,292,413,290,000.00 ✓$899.19
Total dividends collected$17792054110403.60M ✓$6.4K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: EQRXW vs NOBL ($10,000, DRIP)

YearEQRXW PortfolioEQRXW Income/yrNOBL PortfolioNOBL Income/yrGap
1← crossover$450,260$439,560.44$11,120$420.00+$439.1K → EQRXW
2$18,978,664$18,496,885.68$12,357$458.31+$18.97M → EQRXW
3$748,953,345$728,646,173.66$13,721$499.76+$748.94M → EQRXW
4$27,674,743,815$26,873,363,736.79$15,227$544.58+$27674.73M → EQRXW
5$957,652,835,286$928,040,859,403.20$16,885$593.02+$957652.82M → EQRXW
6$31,037,578,041,538$30,012,889,507,782.54$18,713$645.34+$31037578.02M → EQRXW
7$942,293,671,101,243$909,083,462,596,797.50$20,724$701.81+$942293671.08M → EQRXW
8$26,802,238,424,024,828$25,793,984,195,946,500.00$22,938$762.73+$26802238424.00M → EQRXW
9$714,355,176,894,161,700$685,676,781,780,455,000.00$25,372$828.41+$714355176894.14M → EQRXW
10$17,844,003,331,690,041,000$17,079,643,292,413,290,000.00$28,047$899.19+$17844003331690.01M → EQRXW

EQRXW vs NOBL: Complete Analysis 2026

EQRXW — Stock

EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. Its product pipeline in development includes Aumolertinib, an EGFR inhibitor for the treatment of ?EGFR-mutated? non-small cell lung cancer (NSCLC); Sugemalimab, an anti-PD-L1 antibody for the treatment of ?stage III and IV ?NSCLC; Lerociclib, a CDK4/6 inhibitor to treat HR+/HER2- breast cancer; and EQ176, an anti-PD-1?antibody for the treatment of liver cancer. The company has partnerships with Exscientia and AbCellera Biologics Inc. EQRx, Inc. was founded in 2020 and is based in Cambridge, Massachusetts.

Full EQRXW Calculator →

NOBL — ETF

NOBL is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in NOBL shares.

Full NOBL Calculator →
📬

Get this EQRXW vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EQRXW vs SCHDEQRXW vs JEPIEQRXW vs OEQRXW vs KOEQRXW vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.